MEDI-493 humanized monoclonal that neutralizes respiratory syncytial virus: Began Phase I trial of safety, pharmacokinetics, and immunogenicity in healthy adult

MedImmune Inc. (MEDI), Gaithersburg, Md. Product: MEDI-493 humanized monoclonal that neutralizes respiratory syncytial virus (RSV) Indication: RSV disease Status: Began Phase I trial of safety, pharm...